Inicio
Resultado de la búsqueda
4 búsqueda de la palabra clave 'Multiple myeloma'
Clasificado(s) por (Año de edición descendente) Refinar búsqueda Genera el flujo rss de la búsqueda
Enlace permanente de la investigación
Real-world evidence of epidemiology and clinical outcomes in multiple myeloma, findings from the registry of hemato-oncologic malignancies in Colombia, observational study / Kenny Mauricio Gálvez Cárdenas
Título : Real-world evidence of epidemiology and clinical outcomes in multiple myeloma, findings from the registry of hemato-oncologic malignancies in Colombia, observational study Tipo de documento : documento electrónico Autores : Kenny Mauricio Gálvez Cárdenas, Autor asociado al HPTU Fecha de publicación : 2022 Títulos uniformes : Clinical Lymphoma, Myeloma & Leukemia Idioma : Inglés (eng) Palabras clave : Multiple myeloma Colombia Diagnosis Therapy autologous transplantation disease registry real-world Resumen : Multiple Myeloma (MM) is a plasma cell derived clonal disorder that represents around 1% of all newly diagnosed neoplasms. Limited data regarding MM treatment in Latin America is available, and access to novel agents for a substantial portion of the population is limited by their high costs. 1 . In this multicenter cohort study, data on 890 Colombian MM patients are reported with a median follow-up of 18 months (IQR: 7-42 months). Patients were classified by age group (≤ or > 65 years). Median age at diagnosis was 67 years (IQR: 59-75 years) and 47.1% of patients were women. 709 patients (79.6%) received Bortezomib-based schemes as part of the first line, with Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) being the most frequently used (301 patients; 33.8%). Only two hundred and fifty-two patients (28.3%) were consolidated with Autologous Stem Cell Transplantation (ASCT) in first-line therapy. ASCT consolidation and age were the main independent factors influencing outcomes; in the non-ASCT cohort, 5-year overall survival was 48.7% (CI 41.8-55.2) compared to 80.7% (CI 73-86.4) in ASCT patients. This data depicts the reality of MM in Colombia, which likely reflects other Latin American countries, where access barriers to diagnosis and treatment are echoed in advanced stage diagnosis and a low rate of transplants. These seem to negatively impact survival despite the availability of most novel drugs approved in most of the world for this disease. Thus, emphasizing the paradox that prevails in most of the region: availability without equitable access. Mención de responsabilidad : Virginia Abello, William Armando Mantilla, Henry Idrobo, Claudia Lucia Sossa, Luis Antonio Salazar, Angela Pena, Juan Manuel Herrera, Paola Guerrero, Daniel Espinosa, Guillermo Enrique Quintero-Vega, Isabel Munevar, Kenny Galvez, Alicia Henao, Rigoberto Gómez, Jose Domingo Saavedra, Lina María Gaviria, Mónica Osuna y María Victoria Mateos Referencia : Clin Lymphoma Myeloma Leuk. 2021 Dec 13;S2152-2650(21)02478-2. DOI (Digital Object Identifier) : 10.1016/j.clml.2021.12.009 PMID : 35042679 En línea : https://linkinghub.elsevier.com/retrieve/pii/S2152265021024782 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Real-world evidence of epidemiology and clinical outcomes in multiple myeloma, findings from the registry of hemato-oncologic malignancies in Colombia, observational study [documento electrónico] / Kenny Mauricio Gálvez Cárdenas, Autor asociado al HPTU . - 2022.
Obra : Clinical Lymphoma, Myeloma & Leukemia
Idioma : Inglés (eng)
Palabras clave : Multiple myeloma Colombia Diagnosis Therapy autologous transplantation disease registry real-world Resumen : Multiple Myeloma (MM) is a plasma cell derived clonal disorder that represents around 1% of all newly diagnosed neoplasms. Limited data regarding MM treatment in Latin America is available, and access to novel agents for a substantial portion of the population is limited by their high costs. 1 . In this multicenter cohort study, data on 890 Colombian MM patients are reported with a median follow-up of 18 months (IQR: 7-42 months). Patients were classified by age group (≤ or > 65 years). Median age at diagnosis was 67 years (IQR: 59-75 years) and 47.1% of patients were women. 709 patients (79.6%) received Bortezomib-based schemes as part of the first line, with Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) being the most frequently used (301 patients; 33.8%). Only two hundred and fifty-two patients (28.3%) were consolidated with Autologous Stem Cell Transplantation (ASCT) in first-line therapy. ASCT consolidation and age were the main independent factors influencing outcomes; in the non-ASCT cohort, 5-year overall survival was 48.7% (CI 41.8-55.2) compared to 80.7% (CI 73-86.4) in ASCT patients. This data depicts the reality of MM in Colombia, which likely reflects other Latin American countries, where access barriers to diagnosis and treatment are echoed in advanced stage diagnosis and a low rate of transplants. These seem to negatively impact survival despite the availability of most novel drugs approved in most of the world for this disease. Thus, emphasizing the paradox that prevails in most of the region: availability without equitable access. Mención de responsabilidad : Virginia Abello, William Armando Mantilla, Henry Idrobo, Claudia Lucia Sossa, Luis Antonio Salazar, Angela Pena, Juan Manuel Herrera, Paola Guerrero, Daniel Espinosa, Guillermo Enrique Quintero-Vega, Isabel Munevar, Kenny Galvez, Alicia Henao, Rigoberto Gómez, Jose Domingo Saavedra, Lina María Gaviria, Mónica Osuna y María Victoria Mateos Referencia : Clin Lymphoma Myeloma Leuk. 2021 Dec 13;S2152-2650(21)02478-2. DOI (Digital Object Identifier) : 10.1016/j.clml.2021.12.009 PMID : 35042679 En línea : https://linkinghub.elsevier.com/retrieve/pii/S2152265021024782 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares (1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001776 AC-2021-091 Archivo digital Producción Científica Artículos científicos Disponible Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma / Kenny Mauricio Gálvez Cárdenas
Título : Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma Tipo de documento : documento electrónico Autores : Kenny Mauricio Gálvez Cárdenas, Autor asociado al HPTU Fecha de publicación : 2021 Títulos uniformes : Future Oncology Idioma : Inglés (eng) Palabras clave : effectiveness ixazomib multiple myeloma proteasome inhibitor relapsed/refractory routine clinical practice Resumen : Aim: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were integrated and analyzed. Results: At data cut-off, 263 patients from 13 countries were included. Median time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months. Overall response rate was 73%, median progression-free survival, 21.2 months and time-to-next therapy, 33.0 months. Ixazomib/lenalidomide dose reductions were required in 17%/36% of patients; 32%/30% of patients discontinued ixazomib/lenalidomide due to adverse events. Conclusion: The effectiveness and safety of IRd in routine clinical practice are comparable to those reported in TOURMALINE-MM1. Mención de responsabilidad : Roman Hájek, Jiri Minarík, Jan Straub, Ludek Pour, Alexandra Jungova, Jesus G Berdeja, Mario Boccadoro, Lucie Brozova, Andrew Spencer, Frits van Rhee, Jorge Vela-Ojeda, Michael A Thompson, Rafat Abonour, Ajai Chari, Gordon Cook, Caitlin L Costello, Faith E Davies, Vania TM Hungria, Hans C Lee, Xavier Leleu, Noemi Puig, Robert M Rifkin, Evangelos Terpos, Saad Z Usmani, Katja C Weisel, Jeffrey A Zonder, Magda Barinová, Matyáš Kuhn, Jirí Šilar, Lenka Cápková, Kenny Galvez, Jin Lu, Jennifer Elliott, Dawn Marie Stull, Kaili Ren & Vladimír Maisnar Referencia : Future Oncol. 2021 Mar 26. DOI (Digital Object Identifier) : 10.2217/fon-2020-1225 PMID : 33769076 Derechos de uso : CC BY-NC-ND En línea : https://www.futuremedicine.com/doi/10.2217/fon-2020-1225 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma [documento electrónico] / Kenny Mauricio Gálvez Cárdenas, Autor asociado al HPTU . - 2021.
Obra : Future Oncology
Idioma : Inglés (eng)
Palabras clave : effectiveness ixazomib multiple myeloma proteasome inhibitor relapsed/refractory routine clinical practice Resumen : Aim: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were integrated and analyzed. Results: At data cut-off, 263 patients from 13 countries were included. Median time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months. Overall response rate was 73%, median progression-free survival, 21.2 months and time-to-next therapy, 33.0 months. Ixazomib/lenalidomide dose reductions were required in 17%/36% of patients; 32%/30% of patients discontinued ixazomib/lenalidomide due to adverse events. Conclusion: The effectiveness and safety of IRd in routine clinical practice are comparable to those reported in TOURMALINE-MM1. Mención de responsabilidad : Roman Hájek, Jiri Minarík, Jan Straub, Ludek Pour, Alexandra Jungova, Jesus G Berdeja, Mario Boccadoro, Lucie Brozova, Andrew Spencer, Frits van Rhee, Jorge Vela-Ojeda, Michael A Thompson, Rafat Abonour, Ajai Chari, Gordon Cook, Caitlin L Costello, Faith E Davies, Vania TM Hungria, Hans C Lee, Xavier Leleu, Noemi Puig, Robert M Rifkin, Evangelos Terpos, Saad Z Usmani, Katja C Weisel, Jeffrey A Zonder, Magda Barinová, Matyáš Kuhn, Jirí Šilar, Lenka Cápková, Kenny Galvez, Jin Lu, Jennifer Elliott, Dawn Marie Stull, Kaili Ren & Vladimír Maisnar Referencia : Future Oncol. 2021 Mar 26. DOI (Digital Object Identifier) : 10.2217/fon-2020-1225 PMID : 33769076 Derechos de uso : CC BY-NC-ND En línea : https://www.futuremedicine.com/doi/10.2217/fon-2020-1225 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares (1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001715 AC-2021-036 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
2021-036Adobe Acrobat PDF Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study / Kenny Mauricio Gálvez Cárdenas
Título : Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study Tipo de documento : documento electrónico Autores : Kenny Mauricio Gálvez Cárdenas, Autor asociado al HPTU Fecha de publicación : 2020 Títulos uniformes : Leukemia and Lymphoma Idioma : Inglés (eng) Palabras clave : Multiple myeloma Latin America autologous stem cell transplantation proteasome inhibitor Resumen : The aim of this study was to describe clinical and survival characteristics of transplant-eligible multiple myeloma (MM) patients in Latin America (LA), with a special focus on differences between public and private healthcare facilities. We included 1293 patients diagnosed between 2010 and 2018. A great disparity in outcomes and survival between both groups was observed. Late diagnosis and low access to adequate frontline therapy and ASCT in public institutions probably explain these differences. Patients treated with novel drug induction protocols, followed by autologous stem cell transplantation (ASCT) and maintenance, have similar overall survival compared to that published internationally. Mención de responsabilidad : Camila Peña , Eloisa Riva , Natalia Schutz , Luz Tarín-Arzaga , Humberto Martínez-Cordero , Virginia Bove , Rocío Osorio , Mauricio Chandía , Cecilia Beltrán , Javier Schulz , Daniela Cardemil , Carolina Contreras , Carmen Gloria Vergara , Javiera Donoso , Marcela Espinoza , Gabriel La Rocca , Hernán López-Vidal , Pilar León , Christine Rojas Hopkins , Pablo Soto , Sandra Aranda , Vivianne Torres , Macarena Roa , Paola Ochoa , Patricio Jose Duarte , Guillermina Remaggi , Sebastián Yantorno , Ariel Corzo , Soledad Zabaljauregui , Claudia Shanley , Sergio Lopresti , Sergio Orlando , Verónica Verri , Luis Quiroga , Carlos García , Vanesa Fernández , Jhoanna Ramirez , Alicia Molina , María Pacheco , Alex Mite , Inés Reyes , Brenner Sabando , Francisca Ramírez , Claudia Sossa , Virginia Abello , Henry Idrobo , Kenny Mauricio Galvez Cardenas , Domingo Saavedra , Guillermo Quintero , Raimundo Gazitúa , Lina Gaviria , Rigoberto Gomez , Mónica Osuna , Alicia Henao-Uribe , Omar Cantú-Martínez , Referencia : Leuk Lymphoma. 2020 Dec;61(13):3112-3119. DOI (Digital Object Identifier) : 10.1080/10428194.2020.1804558 PMID : 32844699 En línea : https://www.tandfonline.com/doi/full/10.1080/10428194.2020.1804558 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study [documento electrónico] / Kenny Mauricio Gálvez Cárdenas, Autor asociado al HPTU . - 2020.
Obra : Leukemia and Lymphoma
Idioma : Inglés (eng)
Palabras clave : Multiple myeloma Latin America autologous stem cell transplantation proteasome inhibitor Resumen : The aim of this study was to describe clinical and survival characteristics of transplant-eligible multiple myeloma (MM) patients in Latin America (LA), with a special focus on differences between public and private healthcare facilities. We included 1293 patients diagnosed between 2010 and 2018. A great disparity in outcomes and survival between both groups was observed. Late diagnosis and low access to adequate frontline therapy and ASCT in public institutions probably explain these differences. Patients treated with novel drug induction protocols, followed by autologous stem cell transplantation (ASCT) and maintenance, have similar overall survival compared to that published internationally. Mención de responsabilidad : Camila Peña , Eloisa Riva , Natalia Schutz , Luz Tarín-Arzaga , Humberto Martínez-Cordero , Virginia Bove , Rocío Osorio , Mauricio Chandía , Cecilia Beltrán , Javier Schulz , Daniela Cardemil , Carolina Contreras , Carmen Gloria Vergara , Javiera Donoso , Marcela Espinoza , Gabriel La Rocca , Hernán López-Vidal , Pilar León , Christine Rojas Hopkins , Pablo Soto , Sandra Aranda , Vivianne Torres , Macarena Roa , Paola Ochoa , Patricio Jose Duarte , Guillermina Remaggi , Sebastián Yantorno , Ariel Corzo , Soledad Zabaljauregui , Claudia Shanley , Sergio Lopresti , Sergio Orlando , Verónica Verri , Luis Quiroga , Carlos García , Vanesa Fernández , Jhoanna Ramirez , Alicia Molina , María Pacheco , Alex Mite , Inés Reyes , Brenner Sabando , Francisca Ramírez , Claudia Sossa , Virginia Abello , Henry Idrobo , Kenny Mauricio Galvez Cardenas , Domingo Saavedra , Guillermo Quintero , Raimundo Gazitúa , Lina Gaviria , Rigoberto Gomez , Mónica Osuna , Alicia Henao-Uribe , Omar Cantú-Martínez , Referencia : Leuk Lymphoma. 2020 Dec;61(13):3112-3119. DOI (Digital Object Identifier) : 10.1080/10428194.2020.1804558 PMID : 32844699 En línea : https://www.tandfonline.com/doi/full/10.1080/10428194.2020.1804558 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares (1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001386 AC-2020-063 Archivo digital Producción Científica Artículos científicos Disponible Giant forehead plasmacytoma as a growing lump in a patient with multiple myeloma / Yoel Korenfeld Kaplan ; Ricardo Andrés Cardona Quiceno
Título : Giant forehead plasmacytoma as a growing lump in a patient with multiple myeloma Tipo de documento : documento electrónico Autores : Yoel Korenfeld Kaplan, Autor asociado al HPTU ; Ricardo Andrés Cardona Quiceno, Autor asociado al HPTU Fecha de publicación : 2020 Títulos uniformes : Radiology Case Reports Idioma : Inglés (eng) Palabras clave : Multiple myeloma Plasmacytoma Forehead Neoplasms Plasma cell Resumen : Extramedullary plasmacytoma represents less than 5% of plasma cell malignancies, 85% corresponding to head and neck masses. Symptoms are related to compressive effects according to location, aesthetics issues and can be misleading associated with soft tissue disorders. In this case report, we discuss a 70-year-old woman who presented with a 3-month history of a growing painless forehead lump and confusion, for which she had an emergent simple head computed tomography scan. The images revealed a well-defined mass eroding the frontal bone with multiple lytic lesions that were also found along with long bones radiography. The mass biopsy showed a monomorphic plasmatic cell infiltrate, bone marrow studies confirmed the diagnosis of a light chain secreting multiple myeloma. Extramedullary plasmacytoma is a very unusual first presentation form of multiple myeloma and represents a clinical and radiological challenge. A systematic approach of lytic bone lesions along with the differential diagnosis of head masses are skills the clinician should develop to promptly recognize this condition considering further complications of delayed treatment. In this case, the histopathological confirmation allowed the patient to avoid neurosurgery and the early start of systemic chemotherapeutic treatment. Mención de responsabilidad : Adriana M Trejos T, María C Cuartas M, Yoel Korenfeld K y Ricardo Cardona Q Referencia : Radiol Case Rep. 2020 Oct 9;15(12):2589-2593. DOI (Digital Object Identifier) : 10.1016/j.radcr.2020.09.050 PMID : 33082903 Derechos de uso : CC BY-NC-ND En línea : https://linkinghub.elsevier.com/retrieve/pii/S1930-0433(20)30509-4 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Giant forehead plasmacytoma as a growing lump in a patient with multiple myeloma [documento electrónico] / Yoel Korenfeld Kaplan, Autor asociado al HPTU ; Ricardo Andrés Cardona Quiceno, Autor asociado al HPTU . - 2020.
Obra : Radiology Case Reports
Idioma : Inglés (eng)
Palabras clave : Multiple myeloma Plasmacytoma Forehead Neoplasms Plasma cell Resumen : Extramedullary plasmacytoma represents less than 5% of plasma cell malignancies, 85% corresponding to head and neck masses. Symptoms are related to compressive effects according to location, aesthetics issues and can be misleading associated with soft tissue disorders. In this case report, we discuss a 70-year-old woman who presented with a 3-month history of a growing painless forehead lump and confusion, for which she had an emergent simple head computed tomography scan. The images revealed a well-defined mass eroding the frontal bone with multiple lytic lesions that were also found along with long bones radiography. The mass biopsy showed a monomorphic plasmatic cell infiltrate, bone marrow studies confirmed the diagnosis of a light chain secreting multiple myeloma. Extramedullary plasmacytoma is a very unusual first presentation form of multiple myeloma and represents a clinical and radiological challenge. A systematic approach of lytic bone lesions along with the differential diagnosis of head masses are skills the clinician should develop to promptly recognize this condition considering further complications of delayed treatment. In this case, the histopathological confirmation allowed the patient to avoid neurosurgery and the early start of systemic chemotherapeutic treatment. Mención de responsabilidad : Adriana M Trejos T, María C Cuartas M, Yoel Korenfeld K y Ricardo Cardona Q Referencia : Radiol Case Rep. 2020 Oct 9;15(12):2589-2593. DOI (Digital Object Identifier) : 10.1016/j.radcr.2020.09.050 PMID : 33082903 Derechos de uso : CC BY-NC-ND En línea : https://linkinghub.elsevier.com/retrieve/pii/S1930-0433(20)30509-4 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares (1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001632 AC-2020-126 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
2020-126.pdfAdobe Acrobat PDF